{
  "id": "601f1bbd1cb411341a000074",
  "type": "list",
  "question": "Please list 3 small molecule CGRP-Receptor antagonists for migraine",
  "ideal_answer": "Rimegepant and ubrogepant have been developed for acute migraine treatment, while atogepant is studied for migraine prophylaxis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32799325",
    "http://www.ncbi.nlm.nih.gov/pubmed/32020557",
    "http://www.ncbi.nlm.nih.gov/pubmed/19939188",
    "http://www.ncbi.nlm.nih.gov/pubmed/31932515",
    "http://www.ncbi.nlm.nih.gov/pubmed/30725283",
    "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
    "http://www.ncbi.nlm.nih.gov/pubmed/31096904",
    "http://www.ncbi.nlm.nih.gov/pubmed/32173558",
    "http://www.ncbi.nlm.nih.gov/pubmed/31020659",
    "http://www.ncbi.nlm.nih.gov/pubmed/32058712"
  ],
  "snippets": [
    {
      "text": "Ubrogepant (Ubrelvy\u2122) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32020557",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (\u00b1\u2009aura) in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32020557",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " a small molecule CGRP receptor antagonist and an anti-CGRP receptor antibody, can be used concomitantly to treat refractory migraine.METHODS: Case reports are presented of 2 patients participating in a long-term safety study of rimegepant 75 mg oral tablets for acute treatment",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31932515",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The pivotal role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology was identified over 30 years ago, but the successful clinical development of targeted therapies has only recently been realized. This Perspective traces the decades long evolution of medicinal chemistry required to advance small molecule CGRP receptor antagonists, also called gepants, including the current clinical agents rimegepant, vazegepant, ubrogepant, and atogepant. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32058712",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, rimegepant and ubrogepant have been developed for acute migraine treatment, while atogepant is studied for migraine prophylaxis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32173558",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Small molecule CGRP receptor antagonists, gepants, are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (Eptinezumab, Fremanezumab, and Galcanezumab) or the CGRP receptor (Erenumab) effectively prevent migraine attacks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30725283",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "vel classes of drugs, i.e., the 5-HT1F receptor agonists (lasmiditan) and the small molecule CGRP receptor antagonists (gepants). Data on the effects of 5-HT1F receptor agonism in relation to MOH, as well as the effects of chronic CGRP recepto",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31096904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "small-molecule CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase 3 studies for the acute treatment of migraine. Two of these an",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32799325",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: Evaluate the safety and tolerability of oral rimegepant when used for acute treatment concomitantly with a monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) ligand or receptor (CGRP mAb) for the preventive treatment of migraine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32799325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Meanwhile, 1 small-molecule CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase 3 studies for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ithin the past decade. The commentary is supplemented by information presented in journal articles and focuses on the activity of several major pharmaceutical companies in the field.CONCLUSION: Two small molecule CGRP receptor antagonists, olcegepant and telcagepant, have been shown to be clinically efficacious in the treatment of migraine, and thus provide validation o",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19939188",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, orally administered next-generation small molecule CGRP-RAs have been shown to have safety and efficacy in acute treatment (ubrogepant and rimegepant) and prevention (atogepant) of migraine, giving additional CGRP-based therapeutic options for migraine patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31020659",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "ubrogepant, rimegepant, atogepant"
}